Home > Healthcare > Biotechnology > Bioservices > Oncology Based In-vivo CRO Market

Oncology Based In-vivo CRO Market Size

Report ID: GMI12605
Published Date: Dec 2024
Report Format: PDF

Download Free Sample

Oncology Based In-vivo CRO Market Size

The global oncology based in-vivo CRO market size valued at USD 1.4 billion in 2024 and is projected to exhibit 8.8% CAGR from 2025 to 2034. The market is growing due to growing demand for immuno-oncology therapies, advancements in in-vivo models, and growing oncology drug approvals from small biotechnology and pharmaceutical companies.

Oncology Based In-vivo CRO Market

To get key market trends

Download Free Sample

Small biotechnology and pharmaceutical companies are increasingly driving oncology drug approvals, significantly boosting the growth of the oncology-based in-vivo CRO market. These firms are at the forefront of pioneering cancer research, exploring innovative treatments such as CAR-T cell therapy, monoclonal antibodies, and gene therapies. Their specialized focus enables them to address specific unmet needs in oncology. According to a study published by National Center for Biotechnology Information in February 2023, small pharmaceutical companies led the U.S. FDA oncology drug approvals during 2010 and 2020, securing over three times the number of FIC-approved drugs than their larger counterparts, boasting a 46% share against the latter's 14%.

Oncology Based In-vivo CRO Market Report Attributes
Report Attribute	Details
Base Year:	2024
Oncology Based In-vivo CRO Market Size in 2024:	USD 1.4 Billion
Forecast Period:	2025 – 2034
Forecast Period 2025 – 2034 CAGR:	8.8%
2025 – 2034 Value Projection:	USD 3.1 Billion
Historical Data for:	2021 – 2024
No. of Pages:	140
Tables, Charts & Figures:	123
Segments covered:	Service, Model, End Use, and Region
Growth Drivers:	Growing demand for immuno-oncology therapies Advancements in in-vivo models Growing investments in precision oncology Growing oncology drug approvals from small biotechnology and pharmaceutical companies
Pitfalls & Challenges:	Stringent regulatory requirements for oncology drug approvals Presence of strong alternatives

Learn more about the key segments shaping this market

Download Free Sample

Oncology based in-vivo CRO specializes in providing outsourced preclinical and early-stage research services for cancer drug development. These services primarily involve in-vivo studies to evaluate the efficacy, safety, pharmacokinetics, and toxicity of oncology drugs.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global oncology-based in-vivo CRO industry was valued at USD 1.4 billion in 2024 and is projected to grow at an 8.8% CAGR from 2025 to 2034, driven by the increasing demand for immuno-oncology therapies.

The preclinical testing segment held a 33.2% market share in 2024 due to its essential role in the drug development process, mandated by regulatory agencies like the U.S. FDA and EMA.

The U.S. led the North American oncology-based in-vivo CRO market in 2024, generating approximately USD 509 million, primarily due to significant investments in cancer research and a strong presence of pharmaceutical and biotechnology companies.

Key players in the market include Charles River Laboratories, Crown Bioscience, Eurofins Scientific, Evotec SE, ICON plc, IMV, Laboratory Corporation of America Holdings, Medidata, Merck KGaA, OncoOne, Pharmaron, and Taconic Biosciences.